GOSSAMER BIO, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- GOSSAMER BIO, INC. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $201.32M, a 67.87% increase year-over-year.
- GOSSAMER BIO, INC. stock issued during period, value, new issues for the quarter ending 2022-09-30 was $119.93M.
- GOSSAMER BIO, INC. stock issued during period, value, new issues for the quarter ending 2020-06-30 was $117.09M.
- GOSSAMER BIO, INC. stock issued during period, value, new issues for the quarter ending 2019-03-31 was $291.34M.
- GOSSAMER BIO, INC. stock issued during period, value, new issues for fiscal 2023 was $201.32M, a 67.84% increase from fiscal 2022.
- GOSSAMER BIO, INC. stock issued during period, value, new issues for fiscal 2022 was $119.95M.
- GOSSAMER BIO, INC. stock issued during period, value, new issues for fiscal 2020 was $117.09M, a 59.80% decline from fiscal 2019.
- GOSSAMER BIO, INC. stock issued during period, value, new issues for fiscal 2019 was $291.31M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2023-12-31 | $201.32M 10-K · filed 2026-03-17 | |
| 2023-09-30 | $201.32M 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $119.95M 10-K · filed 2025-03-13 | |
| 2022-09-30 | $119.93M 10-Q · filed 2023-11-09 | |
| 2020-12-31 | $117.09M 10-K · filed 2023-03-17 | |
| 2020-06-30 | $117.09M 10-Q · filed 2021-11-08 | |
| 2019-12-31 | $291.31M 10-K · filed 2022-03-03 | |
| 2019-03-31 | $291.34M 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |